ES2341625T3 - Anticuerpos monoclonales anti-cd71 y sus utilizaciones para el tratamiento de las celulas tumorales malignas. - Google Patents
Anticuerpos monoclonales anti-cd71 y sus utilizaciones para el tratamiento de las celulas tumorales malignas. Download PDFInfo
- Publication number
- ES2341625T3 ES2341625T3 ES06795343T ES06795343T ES2341625T3 ES 2341625 T3 ES2341625 T3 ES 2341625T3 ES 06795343 T ES06795343 T ES 06795343T ES 06795343 T ES06795343 T ES 06795343T ES 2341625 T3 ES2341625 T3 ES 2341625T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- baselineskip
- antibody
- substance
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US154262 | 2005-06-15 | ||
US11/154,262 US7736647B2 (en) | 2005-06-15 | 2005-06-15 | Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2341625T3 true ES2341625T3 (es) | 2010-06-23 |
Family
ID=37573538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES06795343T Active ES2341625T3 (es) | 2005-06-15 | 2006-06-14 | Anticuerpos monoclonales anti-cd71 y sus utilizaciones para el tratamiento de las celulas tumorales malignas. |
Country Status (10)
Country | Link |
---|---|
US (2) | US7736647B2 (de) |
EP (1) | EP1896507B1 (de) |
JP (1) | JP5185815B2 (de) |
AT (1) | ATE459653T1 (de) |
CA (1) | CA2612486A1 (de) |
DE (1) | DE602006012672D1 (de) |
DK (1) | DK1896507T3 (de) |
ES (1) | ES2341625T3 (de) |
PL (1) | PL1896507T3 (de) |
WO (1) | WO2007000671A2 (de) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2340317A1 (de) * | 2008-10-23 | 2011-07-06 | F. Hoffmann-La Roche AG | Bestimmung einer für immunglobulin codierenden nukleinsäure |
EP2456472B1 (de) | 2009-07-22 | 2024-03-27 | Actinium Pharmaceuticals, Inc. | Verfahren zur erzeugung von radioimmunkonjugaten |
WO2011130164A2 (en) * | 2010-04-13 | 2011-10-20 | The Regents Of The University Of California | Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer |
FR2959416B1 (fr) * | 2010-05-03 | 2012-06-22 | Monoclonal Antibodies Therapeutics Mat Biopharma | Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament |
PT2646470T (pt) | 2010-11-30 | 2017-05-03 | Hoffmann La Roche | Anticorpos anti-recetor da transferrina de baixa afinidade e a sua utilização na transferência de scfv terapêuticos através da barreira hematoencefálica |
US9623117B2 (en) * | 2011-04-04 | 2017-04-18 | Wisconsin Alumni Research Foundation | Method for selective targeting and entry of bacterial toxins to cells |
MY171343A (en) * | 2011-04-22 | 2019-10-09 | Aptevo Res & Development Llc | Prostate-specific membrane antigen binding proteins and related composition and methods |
WO2013033734A1 (en) | 2011-09-02 | 2013-03-07 | The Trustees Of Columbia University In The City Of New York | Diagnosis and Treatment of Cancer Expressing ILT3 or ILT3 Ligand |
SG11201401518TA (en) | 2011-10-28 | 2014-05-29 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
PT2888283T (pt) | 2012-08-24 | 2018-11-16 | Univ California | Anticorpos e vacinas para serem utilizados no tratamento de cancros que expressam ror1 e inibição de metástases |
RS62956B1 (sr) | 2015-05-04 | 2022-03-31 | Cytomx Therapeutics Inc | Anti-cd71 antitela koja se mogu aktivirati, i postupci njihove upotrebe |
BR112017023868A2 (pt) | 2015-05-04 | 2018-07-24 | Cytomx Therapeutics Inc | anticorpos anti-itga3, anticorpos anti-itga3 ativáveis, e métodos de uso dos mesmos |
EP3325006A4 (de) | 2015-07-17 | 2019-03-06 | The Trustees of Columbia University in the City of New York | Verfahren zur behandlung von cd166-exprimierendem krebs |
EP3352760A4 (de) | 2015-09-21 | 2019-03-06 | Aptevo Research and Development LLC | Cd3-bindende polypeptide |
EP3423089A4 (de) | 2016-03-04 | 2019-10-23 | JN Biosciences, LLC | Anti-tigit-antikörper |
MA45328A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
US20190240346A1 (en) | 2016-06-20 | 2019-08-08 | Genahead Bio, Inc. | Antibody-drug conjugate |
CN109996544A (zh) | 2016-06-27 | 2019-07-09 | 加利福尼亚大学董事会 | 癌症治疗组合 |
EP3554535A4 (de) | 2016-12-14 | 2020-10-21 | Janssen Biotech, Inc. | Pd-l1-bindende fibronectin-typ iii-domänen |
US10611823B2 (en) | 2016-12-14 | 2020-04-07 | Hanssen Biotech, Inc | CD137 binding fibronectin type III domains |
JP7104703B2 (ja) | 2016-12-14 | 2022-07-21 | ヤンセン バイオテツク,インコーポレーテツド | Cd8a結合フィブロネクチンiii型ドメイン |
WO2018165619A1 (en) | 2017-03-09 | 2018-09-13 | Cytomx Therapeutics, Inc. | Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof |
GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
WO2019173771A1 (en) | 2018-03-09 | 2019-09-12 | Cytomx Therapeutics, Inc. | Activatable cd147 antibodies and methods of making and use thereof |
KR102258015B1 (ko) * | 2019-05-15 | 2021-05-27 | 강원대학교 산학협력단 | 암 줄기세포 세포막 단백질에 특이적인 항체 및 그 응용 |
KR102258014B1 (ko) * | 2019-05-15 | 2021-05-27 | 강원대학교 산학협력단 | 암 줄기세포 세포막 단백질에 특이적인 항체 및 그 응용 |
EP3999544A4 (de) * | 2019-07-19 | 2023-08-09 | Wuxi Xdc Singapore Private Limited | Polypeptidkomplex zur konjugation und seine verwendung |
JP2022548310A (ja) | 2019-09-23 | 2022-11-17 | シートムエックス セラピューティクス,インコーポレイテッド | 抗cd47抗体、活性化可能抗cd47抗体、およびその使用方法 |
JP2022551204A (ja) * | 2019-10-14 | 2022-12-07 | アロ・バイオセラピューティクス・カンパニー | Cd71結合フィブロネクチンiii型ドメイン |
US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
CR20220611A (es) | 2020-06-02 | 2023-06-07 | Arcus Biosciences Inc | Anticuerpos anti-tigit |
WO2023034409A1 (en) | 2021-09-01 | 2023-03-09 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5308626A (en) | 1985-06-28 | 1994-05-03 | Toni N. Mariani | Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases |
AU642014B2 (en) | 1990-03-27 | 1993-10-07 | Regents Of The University Of California, The | Method for inhibiting cell growth and compositions useful therefor |
US5762932A (en) | 1990-04-26 | 1998-06-09 | University Of Iowa Research Foundation | Combined treatment of iron depletion and IgG antibody |
US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
AU2005252699B2 (en) | 2004-06-07 | 2010-12-23 | Macrogenics West, Inc. | Transferrin receptor antibodies |
-
2005
- 2005-06-15 US US11/154,262 patent/US7736647B2/en not_active Expired - Fee Related
-
2006
- 2006-06-14 AT AT06795343T patent/ATE459653T1/de active
- 2006-06-14 JP JP2008516448A patent/JP5185815B2/ja not_active Expired - Fee Related
- 2006-06-14 DE DE602006012672T patent/DE602006012672D1/de active Active
- 2006-06-14 WO PCT/IB2006/002331 patent/WO2007000671A2/en active Application Filing
- 2006-06-14 DK DK06795343.0T patent/DK1896507T3/da active
- 2006-06-14 EP EP06795343A patent/EP1896507B1/de not_active Not-in-force
- 2006-06-14 US US11/922,025 patent/US8409573B2/en not_active Expired - Fee Related
- 2006-06-14 ES ES06795343T patent/ES2341625T3/es active Active
- 2006-06-14 CA CA002612486A patent/CA2612486A1/en not_active Abandoned
- 2006-06-14 PL PL06795343T patent/PL1896507T3/pl unknown
Also Published As
Publication number | Publication date |
---|---|
CA2612486A1 (en) | 2007-01-04 |
EP1896507B1 (de) | 2010-03-03 |
WO2007000671A3 (en) | 2007-04-26 |
US20060286030A1 (en) | 2006-12-21 |
DE602006012672D1 (de) | 2010-04-15 |
PL1896507T3 (pl) | 2010-08-31 |
ATE459653T1 (de) | 2010-03-15 |
DK1896507T3 (da) | 2010-06-07 |
JP2009509497A (ja) | 2009-03-12 |
WO2007000671A2 (en) | 2007-01-04 |
US8409573B2 (en) | 2013-04-02 |
US20110311544A1 (en) | 2011-12-22 |
JP5185815B2 (ja) | 2013-04-17 |
US7736647B2 (en) | 2010-06-15 |
EP1896507A2 (de) | 2008-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2341625T3 (es) | Anticuerpos monoclonales anti-cd71 y sus utilizaciones para el tratamiento de las celulas tumorales malignas. | |
JP7316862B2 (ja) | 小細胞肺癌に対する標的療法 | |
Ahmed et al. | Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy | |
CA2107553C (en) | Monoclonal antibodies to stem cell factor receptors | |
EP1470146B1 (de) | Antikörper gegen das muc18-antigen | |
EP1467757B1 (de) | Verwendung von antikörpern gegen das muc18-antigen | |
JP2005516965A (ja) | 抗muc18抗体を使用する方法 | |
JP2000511421A (ja) | ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用 | |
US20240197931A1 (en) | Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells | |
CN101622342A (zh) | 减轻癌性疾病的抗体 | |
ES2278309T3 (es) | Anticuerpos que modifican una enfermedad cancerosa. | |
JP2008513361A (ja) | 癌性疾患修飾性抗体 | |
CN101622341A (zh) | 减轻癌性疾病的抗体 | |
Plüss et al. | Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen | |
US10519246B2 (en) | Anti-fibroblast activation protein (FAP) antibodies for treatment and diagnosis | |
Bakács et al. | A bispecific antibody prolongs survival in mice bearing lung metastases of syngeneic mammary adenocarcinoma | |
Cianfriglia et al. | Ceacam1 is a privileged cell surface antigen to design novel scfv mediated-immunotherapies of melanoma, lung cancer and other types of tumors | |
Ditzel et al. | Immunoscintigraphy of colon cancers with the human monoclonal antibody cou‐1 | |
Petersburg | Prosthetic Antigen Receptors As A Platform For Solid Tumor Immunotherapy | |
KR20220003041A (ko) | 조합 치료법 | |
Jensenius | cou-I |